The Infectious Immunology industry trends over the past 18 months reflect accelerated innovation driven by emerging pathogens and evolving diagnostic demands. Key developments include strategic partnerships such as GSK’s collaboration with Vir Biotechnology to advance next-generation antiviral therapies, leveraging monoclonal antibodies for rapid response to outbreaks. Mergers & acquisitions saw Thermo Fisher Scientific acquire a diagnostics firm specializing in rapid molecular testing, bolstering its global infectious disease detection capabilities. Product launches highlight the rise of CRISPR-based diagnostic tools, with Sherlock Biosciences securing FDA Emergency Use Authorization for a SARS-CoV-2 test, while Moderna expanded its mRNA pipeline to include a universal influenza vaccine candidate. Regulatory changes underscored the FDA’s updated Antibiotic Development Incentive Policy, aiming to fast-track approvals for novel antimicrobials amid rising resistance. Consumer and enterprise trends shifted toward decentralized, point-of-care testing solutions, driven by healthcare providers’ demand for agility. Funding rounds surged, with startups like Adaptive Biotechnologies securing $250M to scale AI-powered immunology platforms, signaling investor confidence in data-driven infectious disease surveillance. Collectively, these trends position the market for sustained growth, prioritizing speed, precision, and global health resilience.
